Publication | Closed Access

An HER3-targeting antibody–drug conjugate incorporating a DNA topoisomerase I inhibitor U3-1402 conquers EGFR tyrosine kinase inhibitor-resistant NSCLC

Drug TargetingNovel TherapyImmunologyHer3-targeting Antibody–drug ConjugateImmunotherapeuticsAnti-cancer AgentTumor TargetingTargeted TherapyImmunotherapyMedicineCell BiologyDna Topoisomerase